Skip to main content
Top
Published in: Esophagus 4/2016

01-10-2016 | Original Article

Gastro esophageal reflux disease (GERD) prevalence and related risk factors in north of Iran

Authors: Behnam Rabiee, Nima Motamed, Vahid Hosseini, Gholam Reza Hemasi, Mansooreh Maadi, Farhad Zamani

Published in: Esophagus | Issue 4/2016

Login to get access

Abstract

Background

Gastroesophageal reflux disease (GERD) is one of the most frequent disorders in daily clinical practice with numerous associated consequences. A large number of studies were conducted to determine the prevalence of GERD and its associated risk factors which led to inconsistent results. The present study was performed to evaluate the prevalence of GERD and its related risk factors in north of Iran.

Methods

Nine hundred and thirty-three educated participants aged 18–77 years who had at least a High School Diploma were enrolled in the present study. Validated Persian version of Gastroesopahageal reflux questionnaire was used to collect the data. To determine the GERD associated risk factors, logistic regression was performed.

Results

The prevalence of GERD was 53.5 % (frequent GERD: 12.1 %). Among seven potential risk factors, the positive history of reflux in first relatives (OR = 2.37, CI = 1.76–3.20, p value < 0.001) and asthma (OR = 2.605, CI = 1.553–4.368, p < 0.001) were significantly associated with GERD. Spouse history of GERD in interaction with first relatives history of GERD and smoking was significantly associated with GERD too.

Conclusion

The prevalence of GERD is increasing in our country compared to previus studies, which may lead to serious increment of malignant conditions such as esophagus adenocarcinoma.
Literature
1.
go back to reference Jones R. Gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol Suppl. 1995;211:35–8.CrossRefPubMed Jones R. Gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol Suppl. 1995;211:35–8.CrossRefPubMed
2.
go back to reference Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900–20 (quiz 43).CrossRefPubMed Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900–20 (quiz 43).CrossRefPubMed
3.
go back to reference El-Serag HB, Sweet S, Winchester CC, et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871–80.CrossRefPubMed El-Serag HB, Sweet S, Winchester CC, et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871–80.CrossRefPubMed
4.
go back to reference Sonnenberg A. Effects of environment and lifestyle on gastroesophageal reflux disease. Dig Dis. 2011;29(2):229–34.CrossRefPubMed Sonnenberg A. Effects of environment and lifestyle on gastroesophageal reflux disease. Dig Dis. 2011;29(2):229–34.CrossRefPubMed
5.
go back to reference Wong BC, Kinoshita Y. Systematic review on epidemiology of gastroesophageal reflux disease in Asia. Clin Gastroenterol hepatol Off Clin Pract J Am Gastroenterol Assoc. 2006;4(4):398–407. Wong BC, Kinoshita Y. Systematic review on epidemiology of gastroesophageal reflux disease in Asia. Clin Gastroenterol hepatol Off Clin Pract J Am Gastroenterol Assoc. 2006;4(4):398–407.
6.
go back to reference Delavari A, Moradi G, Birjandi F, et al. The prevalence of gastroesophageal reflux disease (GERD) in the Islamic Republic of Iran: a systematic review. Middle East J Digest Dis. 2012;4(1):5–15. Delavari A, Moradi G, Birjandi F, et al. The prevalence of gastroesophageal reflux disease (GERD) in the Islamic Republic of Iran: a systematic review. Middle East J Digest Dis. 2012;4(1):5–15.
7.
go back to reference Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340(11):825–31.CrossRefPubMed Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340(11):825–31.CrossRefPubMed
8.
go back to reference Bruley Des Varannes S, Marek L, Humeau B, et al. Gastroesophageal reflux disease in primary care. Prevalence, epidemiology and quality of life of patients. Gastroenterol Clin Biol. 2006;30(3):364–70.CrossRefPubMed Bruley Des Varannes S, Marek L, Humeau B, et al. Gastroesophageal reflux disease in primary care. Prevalence, epidemiology and quality of life of patients. Gastroenterol Clin Biol. 2006;30(3):364–70.CrossRefPubMed
9.
go back to reference Gisbert JP, Cooper A, Karagiannis D, et al. Impact of gastroesophageal reflux disease on work absenteeism, presenteeism and productivity in daily life: a European observational study. Health Qual Life Outcomes. 2009;7:90.CrossRefPubMedPubMedCentral Gisbert JP, Cooper A, Karagiannis D, et al. Impact of gastroesophageal reflux disease on work absenteeism, presenteeism and productivity in daily life: a European observational study. Health Qual Life Outcomes. 2009;7:90.CrossRefPubMedPubMedCentral
10.
go back to reference Wahlqvist P, Reilly MC, Barkun A. Systematic review: the impact of gastro-oesophageal reflux disease on work productivity. Aliment Pharmacol Ther. 2006;24(2):259–72.CrossRefPubMed Wahlqvist P, Reilly MC, Barkun A. Systematic review: the impact of gastro-oesophageal reflux disease on work productivity. Aliment Pharmacol Ther. 2006;24(2):259–72.CrossRefPubMed
11.
go back to reference Nouraie M, Razjouyan H, Assady M, et al. Epidemiology of gastroesophageal reflux symptoms in Tehran, Iran: a population-based telephone survey. Arch Iran Med. 2007;10(3):289–94.PubMed Nouraie M, Razjouyan H, Assady M, et al. Epidemiology of gastroesophageal reflux symptoms in Tehran, Iran: a population-based telephone survey. Arch Iran Med. 2007;10(3):289–94.PubMed
12.
go back to reference Zheng Z, Nordenstedt H, Pedersen NL, et al. Lifestyle factors and risk for symptomatic gastroesophageal reflux in monozygotic twins. Gastroenterology. 2007;132(1):87–95.CrossRefPubMed Zheng Z, Nordenstedt H, Pedersen NL, et al. Lifestyle factors and risk for symptomatic gastroesophageal reflux in monozygotic twins. Gastroenterology. 2007;132(1):87–95.CrossRefPubMed
13.
14.
go back to reference Nasseri-Moghaddam S, Mofid A, Ghotbi MH, et al. Epidemiological study of gastro-oesophageal reflux disease: reflux in spouse as a risk factor. Aliment Pharmacol Ther. 2008;28(1):144–53.CrossRefPubMed Nasseri-Moghaddam S, Mofid A, Ghotbi MH, et al. Epidemiological study of gastro-oesophageal reflux disease: reflux in spouse as a risk factor. Aliment Pharmacol Ther. 2008;28(1):144–53.CrossRefPubMed
15.
go back to reference Zamani F, Sohrabi M, Alipour A, et al. Prevalence and risk factors of cholelithiasis in Amol city, northern Iran: a population based study. Arch Iran Med. 2014;17(11):750–4.PubMed Zamani F, Sohrabi M, Alipour A, et al. Prevalence and risk factors of cholelithiasis in Amol city, northern Iran: a population based study. Arch Iran Med. 2014;17(11):750–4.PubMed
16.
go back to reference Locke GR, Talley NJ, Weaver AL, et al. A new questionnaire for gastroesophageal reflux disease. Mayo Clin Proc. 1994;69(6):539–47.CrossRefPubMed Locke GR, Talley NJ, Weaver AL, et al. A new questionnaire for gastroesophageal reflux disease. Mayo Clin Proc. 1994;69(6):539–47.CrossRefPubMed
17.
go back to reference Austin GL, Thiny MT, Westman EC, et al. A very low-carbohydrate diet improves gastroesophageal reflux and its symptoms. Dig Dis Sci. 2006;51(8):1307–12.CrossRefPubMed Austin GL, Thiny MT, Westman EC, et al. A very low-carbohydrate diet improves gastroesophageal reflux and its symptoms. Dig Dis Sci. 2006;51(8):1307–12.CrossRefPubMed
18.
go back to reference Meining A, Classen M. The role of diet and lifestyle measures in the pathogenesis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2000;95(10):2692–7.CrossRefPubMed Meining A, Classen M. The role of diet and lifestyle measures in the pathogenesis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2000;95(10):2692–7.CrossRefPubMed
19.
20.
go back to reference Trudgill N. Familial factors in the etiology of gastroesophageal reflux disease, Barrett’s esophagus, and esophageal adenocarcinoma. Chest Surg Clin N Am. 2002;12(1):15–24.CrossRefPubMed Trudgill N. Familial factors in the etiology of gastroesophageal reflux disease, Barrett’s esophagus, and esophageal adenocarcinoma. Chest Surg Clin N Am. 2002;12(1):15–24.CrossRefPubMed
21.
go back to reference Trudgill NJ, Kapur KC, Riley SA. Familial clustering of reflux symptoms. Am J Gastroenterol. 1999;94(5):1172–8.CrossRefPubMed Trudgill NJ, Kapur KC, Riley SA. Familial clustering of reflux symptoms. Am J Gastroenterol. 1999;94(5):1172–8.CrossRefPubMed
22.
go back to reference Cameron AJ, Lagergren J, Henriksson C, et al. Gastroesophageal reflux disease in monozygotic and dizygotic twins. Gastroenterology. 2002;122(1):55–9.CrossRefPubMed Cameron AJ, Lagergren J, Henriksson C, et al. Gastroesophageal reflux disease in monozygotic and dizygotic twins. Gastroenterology. 2002;122(1):55–9.CrossRefPubMed
24.
go back to reference Zhai R, Chen F, Liu G, et al. Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(14):2445–51.CrossRef Zhai R, Chen F, Liu G, et al. Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(14):2445–51.CrossRef
25.
go back to reference Nandurkar S, Locke GR 3rd, Fett S, et al. Relationship between body mass index, diet, exercise and gastro-oesophageal reflux symptoms in a community. Aliment Pharmacol Ther. 2004;20(5):497–505.CrossRefPubMed Nandurkar S, Locke GR 3rd, Fett S, et al. Relationship between body mass index, diet, exercise and gastro-oesophageal reflux symptoms in a community. Aliment Pharmacol Ther. 2004;20(5):497–505.CrossRefPubMed
26.
go back to reference Ruigomez A, Rodriguez LA, Wallander MA, et al. Gastroesophageal reflux disease and asthma: a longitudinal study in UK general practice. Chest. 2005;128(1):85–93.CrossRefPubMed Ruigomez A, Rodriguez LA, Wallander MA, et al. Gastroesophageal reflux disease and asthma: a longitudinal study in UK general practice. Chest. 2005;128(1):85–93.CrossRefPubMed
27.
go back to reference Martins AA. Asthma and gastroesophageal reflux disease. Jornal brasileiro de pneumologia: publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia. 2007;33(2):xi–xii. Martins AA. Asthma and gastroesophageal reflux disease. Jornal brasileiro de pneumologia: publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia. 2007;33(2):xi–xii.
28.
go back to reference Kotzan J, Wade W, Yu HH. Assessing NSAID prescription use as a predisposing factor for gastroesophageal reflux disease in a Medicaid population. Pharm Res. 2001;18(9):1367–72.CrossRefPubMed Kotzan J, Wade W, Yu HH. Assessing NSAID prescription use as a predisposing factor for gastroesophageal reflux disease in a Medicaid population. Pharm Res. 2001;18(9):1367–72.CrossRefPubMed
Metadata
Title
Gastro esophageal reflux disease (GERD) prevalence and related risk factors in north of Iran
Authors
Behnam Rabiee
Nima Motamed
Vahid Hosseini
Gholam Reza Hemasi
Mansooreh Maadi
Farhad Zamani
Publication date
01-10-2016
Publisher
Springer Japan
Published in
Esophagus / Issue 4/2016
Print ISSN: 1612-9059
Electronic ISSN: 1612-9067
DOI
https://doi.org/10.1007/s10388-016-0536-6

Other articles of this Issue 4/2016

Esophagus 4/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.